Boston Scientific Corp.
Revenue Breakdown
| Fiscal Year | Endoscopy | Urology | Neuromodulation | Cardiac Rhythm Management | Electrophysiology | Interventional Cardiology | Peripheral Interventions | Watchman | Interventional Cardiology & Vascular Therapies | Interventional Oncology & Embolization | Specialty Pharmaceuticals/Other |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2017 | $1.62B | $1.12B | $635.0M | $1.89B | $278.0M | $2.42B | $1.08B | — | — | — | — |
| FY2018 | $1.76B | $1.25B | $779.0M | $1.95B | $311.0M | $2.59B | $1.19B | — | — | — | — |
| FY2019 | $1.89B | $1.41B | $873.0M | $1.94B | $329.0M | $2.82B | $1.39B | — | — | — | $81.0M |
| FY2020 | $1.78B | $1.29B | $761.0M | $1.70B | $287.0M | $2.30B | $1.58B | — | — | — | $219.0M |
| FY2021 | $2.14B | $1.58B | $909.0M | $2.02B | $365.0M | $3.04B | $1.82B | — | — | — | $13.0M |
| FY2022 | $2.22B | $1.77B | $917.0M | $2.10B | $585.0M | $2.23B | $1.90B | $1.02B | — | — | $-60.0M |
| FY2023 | $2.48B | $1.96B | $976.0M | $2.22B | $800.0M | $2.42B | $2.11B | $1.27B | — | — | $0 |
| FY2024 | $2.69B | $2.20B | $1.11B | $2.28B | $1.90B | $2.65B | $2.41B | $1.52B | — | — | $0 |
| FY2025 | $2.92B | $2.71B | $1.20B | $2.33B | $3.33B | — | — | $1.96B | $4.64B | $996.0M | — |